WallStSmart
TECX

Tectonic Therapeutic, Inc.

NASDAQ: TECX · HEALTHCARE · BIOTECHNOLOGY

$28.81
+3.61% today

Updated 2026-06-03

Market cap
$553.62M
P/E ratio
P/S ratio
EPS (TTM)
$-4.46
Dividend yield
52W range
$14 – $36
Volume
0.2M

Tectonic Therapeutic, Inc. (TECX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$45000.00$380000.00$850000.00$1.21M$1.40M$4.17M$617000.00$1.65M
Gross profit$-45000.00$-380000.00$-850000.00$-1.21M$-1.40M$-4.17M$-617000.00$-1.65M
Gross margin
R&D$2.66M$15.19M$35.09M$54.97M$86.03M$10.98M$25.65M$36.97M$41.36M$63.49M
SG&A$4.63M$7.18M$7.68M$16.65M$20.55M
Operating income$-4.63M$-18.39M$-46.24M$-75.81M$-120.23M$-15.61M$-32.83M$-44.65M$-58.02M$-84.04M
Operating margin
EBITDA$-4.66M$-18.60M$-45.98M$-72.11M$-118.50M$-8.12M$-31.03M$-41.19M$-56.23M$-71.48M
EBITDA margin
EBIT$-4.63M$-18.65M$-46.36M$-72.97M$-119.71M$-8.48M$-32.04M$-42.67M$-57.88M$-72.86M
Interest expense$224000.00$144000.00$152000.00$107000.00$63000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-4.66M$-18.65M$-46.36M$-72.97M$-119.71M$-8.93M$-32.18M$-42.82M$-57.98M$-74.15M
Net income growth (YoY)-299.8%-148.6%-57.4%-64.1%+92.5%-260.5%-33.1%-35.4%-27.9%
Profit margin

Frequently asked questions

How much free cash flow does TECX generate?

TECX produced $-60.29M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is TECX's balance sheet healthy?

TECX holds $253.80M in cash and equivalents against — in long-term debt, on $251.33M of shareholder equity. That debt is best read against the cash flow the business throws off each year.